Unsere Publikationen

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Link
https://doi.org/10.1007/s00415-021-10931-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group.
Verlag
J Neurol. 2022 Jun;269(6):3276-3285.
Zum Eintrag

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Link
https://doi.org/10.1007/s12325-022-02100-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Rieckmann P, Ziemssen T, Penner IK, Raji A, Wagner T, Richter J, Zettl UK.
Verlag
Adv Ther. 2022 Jun;39(6):2749-2760.
Zum Eintrag

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

Link
https://doi.org/10.3389/fneur.2022.913616
Tags
Multiple SkleroseMS BehandlungManagement & Science
Jahr
2022
Autoren
Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
Verlag
Front Neurol. 2022 Jun 27;13:913616.
Zum Eintrag

Evaluation of the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis from a societal perspective in Germany

Link
https://doi.org/10.1177/20552173221085741
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Koeditz D, Frensch J, Bierbaum M, Ness N-, Ettle B, Ziemssen T.
Verlag
Nervenheilkunde 2022;41(7-8):502-508.
Zum Eintrag

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Link
https://doi.org/10.1007/s10354-022-00931-4
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Moser T, Ziemssen T, Sellner J.
Verlag
Wien Med Wochenschr 2022;172(15-16):365-372.
Zum Eintrag

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

Link
https://doi.org/10.3390/ijms232213759
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Akgün K, Behrens J, Schriefer D, Ziemssen T.
Verlag
Int J Mol Sci 2022;23(22).
Zum Eintrag

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Link
https://doi.org/10.1186/s42466-022-00219-3
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, Kölsche T, Korsen M, Grothe M, Groppa S, Luessi F, Engel S, Nelles G, Bonmann E, Roick H, Friedrich A, Knorn P, Landefeld H, Biro Z, Ernst M, Bayas A, Menacher M, Akgün K, Kleinschnitz C, Ruck T, Ziemssen T, Pul R, Meuth SG.
Verlag
Neurol Res Pract. 2022 Nov 7;4(1):55.
Zum Eintrag

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Link
https://doi.org/10.1177/1756286421993999
Tags
Multiple SkleroseMS Behandlung
Jahr
2021
Autoren
Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, de Seze J, Repovic P, Chen H, Hanna J, Messer J, Miller C, Naismith RT.
Verlag
Ther Adv Neurol Disord. 2021 Mar 19;14:1756286421993999
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-